{
event: "article_read",
name: `BR1DGE Talk Show: Timing Matters - The Evolving Story of Type 1 Diabetes`,
author: ``,
tags: `Disease Burden | Staging | Early Detection | Talk Show`,
publication_date: ``,
interaction_type: "content"
}
Resource
BR1DGE
Disease Burden
Staging
Early Detection
Talk Show
BR1DGE Talk Show: Timing Matters - The Evolving Story of Type 1 Diabetes
Explore how decades of advancements in biomarkers, genetics, and staging frameworks have culminated in our ability to “see” T1D before symptoms emerge.
Learning Objectives
Understand the autoimmune basis of type 1 diabetes and the role of autoantibodies
Describe the early stages of type 1 diabetes and the criteria used for staging
Explain the benefits of population screening for early detection of type 1 diabetes, including the reduction of diabetic ketoacidosis (DKA)
Summary
In this episode of the BR1DGE Talk Show, host Vivienne Parry joins experts Jacques Beltrand and Luis Castaño to discuss the paradigm shift in our understanding of type 1 diabetes. They explore the autoimmune nature of T1D, which can be detected years before clinical symptoms appear by screening for autoantibodies. The experts review data from population screening studies, which show a dramatic reduction in life-threatening diabetic ketoacidosis (DKA) at diagnosis and open a crucial window to potentially delay the need for insulin.
BR1DGE is a non-promotional global medical education program designed to advance understanding around presymptomatic type 1 diabetes and is provided by Sanofi.
This website is intended only for use by healthcare professionals in Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, India, Ireland, Israel, Italy, Japan, Kingdom of Saudi Arabia, Kuwait, Luxembourg, Mexico, Norway, Poland, Portugal, Qatar, Russian Federation, Spain, Sweden, The Netherlands, The United Arab Emirates, and The United Kingdom (UK).
Note: Healthcare professionals from Ireland or The UK must click the second link below to be redirected to the local website.
Are you a healthcare professional from one of the countries listed above?
You are now being redirected to a third-party website.
You are now being redirected to a third-party website.
You are about to leave the Sanofi-sponsored BR1DGE website and enter a third-party website. This link is provided as a service and does not imply endorsement by Sanofi of the information contained on the third-party website. Sanofi is not responsible for the content, views, or privacy policies of this third-party site.
.jpg/jcr:content/thumb%20(1).jpg)